Treatment of ulcerative colitis

Purpose of review Ulcerative colitis is a chronic inflammatory disease of the colon of unknown cause that is characterized by alternating intervals of active and inactive disease in 80–90% of patients. The primary goal of treatment is to induce and maintain remission using therapy tailored to the individual patient. The purpose of this review was to describe the management of ulcerative colitis with emphasis on the use of anti-tumor necrosis factor (TNF) agents. Recent findings Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis. In a recent study, infliximab was found to have comparable efficacy to cyclosporine in treatment of acute severe refractory to corticosteroids ulcerative colitis. Summary Anti-TNF therapy should be initiated in patients with acute severe refractory to corticosteroids ulcerative colitis and in patients with moderate-to-severe ulcerative colitis who are not responsive to conventional treatment with aminosalicylates, corticosteroids and immune modulators. Alternatives to infliximab are ADA and golimumab. Future research is needed to further assess the long-term efficacy and safety of ADA and golimumab in ulcerative colitis.

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  L. Bazzano,et al.  Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. , 2013, Gastroenterology.

[3]  W. Sandborn,et al.  52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants , 2013, Inflammatory bowel diseases.

[4]  J. Coffey,et al.  Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis , 2013, International Journal of Colorectal Disease.

[5]  S. Travis,et al.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study , 2013, Gut.

[6]  P. Rutgeerts,et al.  Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease: An Open-label, Multicenter, Prospective Trial , 2013, Inflammatory bowel diseases.

[7]  G. D'Haens,et al.  One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 , 2013, Alimentary pharmacology & therapeutics.

[8]  R. Bagin,et al.  Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. , 2012, Gastroenterology.

[9]  J. Gisbert,et al.  Overall Incidence of Hepatosplenic T Cell Lymphoma in Patients With Inflammatory Bowel Disease on Thiopurines: A Meta-Analysis of Three Population Based Studies , 2011 .

[10]  P. Moayyedi,et al.  Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[11]  D. Rubin,et al.  Randomised clinical trial: delayed‐release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing – ASCEND I and II combined analysis , 2011, Alimentary pharmacology & therapeutics.

[12]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[13]  M. Wasik,et al.  Hepatosplenic T-Cell Lymphoma in Inflammatory Bowel Disease: A Possible Thiopurine-Induced Chromosomal Abnormality , 2010, The American Journal of Gastroenterology.

[14]  W. Blonski,et al.  Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. , 2010, Gastroenterology clinics of North America.

[15]  J. West,et al.  Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case–Control Study , 2010, The American Journal of Gastroenterology.

[16]  J. Gisbert,et al.  W1193 Safety of Thiopurine Therapy in Inflammatory Bowel Disease (IBD): Long-Term Follow-up Study of 3,900 Patients , 2010 .

[17]  P. Gaburri,et al.  Azathioprine maintains long‐term steroid‐free remission through 3 years in patients with steroid‐dependent ulcerative colitis† , 2010, Inflammatory bowel diseases.

[18]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[19]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[20]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[21]  L. Dalal.  Medical treatment of ulcerative colitis. , 2007, The Journal of the Association of Physicians of India.

[22]  A. Akobeng,et al.  Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. , 2006, The Cochrane database of systematic reviews.

[23]  P. Rutgeerts,et al.  Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  J. Lewis,et al.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.

[25]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[26]  W. Tremaine,et al.  American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[27]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[28]  C. Brensinger,et al.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.

[29]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[30]  P. Marteau,et al.  An unusual cause of soft tissue infection , 2005, Gut.

[31]  O. Paoluzi,et al.  Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study , 2005, Alimentary pharmacology & therapeutics.

[32]  K. Soares-Weiser,et al.  Cyclosporine A for induction of remission in severe ulcerative colitis. , 2005, The Cochrane database of systematic reviews.

[33]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[34]  K. Petraki,et al.  A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis , 2004, American Journal of Gastroenterology.

[35]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[36]  H. Ogata,et al.  Measurement of Colonic Mucosal Concentrations of 5-Aminosalicylic Acid Is Useful for Estimating Its Therapeutic Efficacy in Distal Ulcerative Colitis: Comparison of Orally Administered Mesalamine and Sulfasalazine , 2001, Inflammatory bowel diseases.

[37]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[38]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[39]  Caprilli,et al.  Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment , 1999, Alimentary pharmacology & therapeutics.

[40]  P. Munkholm,et al.  Course of ulcerative colitis: analysis of changes in disease activity over years. , 1994, Gastroenterology.

[41]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[42]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[43]  S. Kreiner,et al.  Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. , 1991, Scandinavian journal of gastroenterology.

[44]  L. Melton,et al.  Prognosis of chronic ulcerative colitis in a community. , 1987, Gut.

[45]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[46]  S. Kreiner,et al.  Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen. , 1985, Gut.

[47]  J. Lennard-jones,et al.  Controlled trial of azathioprine in chronic ulcerative colitis. , 1982, British medical journal.

[48]  S. Truelove,et al.  FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITIS , 1978, The Lancet.

[49]  A. McKendrick,et al.  DENTAL CARIES AND SUGAR INTAKE , 1975, The Lancet.

[50]  B. Levin,et al.  A controlled trial of azathioprine in the management of chronic ulcerative colitis. , 1975, Gastroenterology.

[51]  R. Caprilli,et al.  A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis , 1975, The American Journal of Digestive Diseases.

[52]  D. Jewell,et al.  Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial , 1974, British medical journal.

[53]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[54]  J. H. Baron,et al.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION. , 1965, Lancet.

[55]  J. H. Baron,et al.  Out-patient Treatment of Ulcerative Colitis , 1962, British medical journal.

[56]  F. Jones,et al.  An Assessment of Prednisone, Salazopyrin, and Topical Hydrocortisone Hemisuccinate Used as Out-patient Treatment for Ulcerative Colitis , 1960, Gut.

[57]  S. Truelove,et al.  Cortisone and Corticotrophin in Ulcerative Colitis , 1959, British medical journal.

[58]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[59]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[60]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[61]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.

[62]  D. Porter,et al.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  A. Griffiths,et al.  Oral budesonide for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[64]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[65]  J. Macdonald,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2006, The Cochrane database of systematic reviews.

[66]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.

[67]  J. Goldberg,et al.  Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. , 1983, Gastroenterology.

[68]  J. Lennard-jones,et al.  A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. , 1981, Digestion.

[69]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.